你即將離開本站

並前往https://www.clinicaltrialsarena.com/comment/protalixs-phase-iii-asset-for-fabry-could-struggle-to-demonstrate-superiority-over-fabrazyme-but-immunogenicity-benefits-support-regulatory-chances-experts-say/

Protalix's PRX-102 could struggle to show superiority over ...

But the heterogeneity of Fabry disease patients and the multitude of confounding factors that influence eGFR decline weaken the prospects of ...

確定！ 回上一頁

查詢 「PRX Impact Factor」的人也找了：

  1. PRL impact Factor
    2.
  2. PRX Quantum impact factor
    3.
  3. Physical Review Research impact factor
    4.
  4. Physical Review X
    5.
  5. Physical Review B
    6.
  6. Physical Review A impact Factor 2020
    7.
  7. Physical Review Letters
    8.
  8. Science impact factor
    9.